Compare Marsh & McLennan Companies, Inc. (MRSH) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Nuwellis Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $188.85 (market cap $90.13B), while Nuwellis Inc trades at $1.38 (market cap $515.48K). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 174846.7× Nuwellis Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.1% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| MRSH | NUWE | |
|---|---|---|
Market Cap | $90.13B | $515.48K |
Sector | Financials | Technology |
52-Week High | $211.21 | $220.50 |
52-Week Low | $157.32 | $1.30 |
Enterprise Value | $110.81B | -$1.29M |
Dividend Yield | 2.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $188.69, down 1.34% on the day, with a bullish technical signal supported by moving averages and an oversold RSI. The company reported strong Q2 2026 earnings, beating estimates with $2.96 EPS, and maintains solid fundamentals including a 14.24% net income margin and 25.72% ROE. Recent acquisitions, such as MMA's deal for Accel, highlight strategic growth initiatives.
The outlook remains positive with a consensus price target of $202.89, though risks include margin pressure from rising expenses and soft P&C pricing. Institutional activity shows mixed positions, with Bank of America reducing holdings while others like Ashton Thomas Securities added new stakes, reflecting cautious optimism.
NUWE trades at $1.41, down 4.73% on the day, with a bearish technical signal from moving averages despite bullish oscillators. The company reported revenue growth of 14% year-over-year for Q2 2026 (GlobeNewsWire, 2026-07-27) but continues to post significant net losses, with a net income margin of -217.22%. Recent developments include a reverse stock split, a new CEO appointment, and capital raises extending the cash runway into Q2 2027.
The outlook remains high-risk due to persistent losses and negative profitability metrics, though revenue growth and strategic expansions in pediatric care offer potential. Investment opportunity hinges on the company's ability to achieve profitability; key risks include cash burn, competitive pressures, and execution challenges in scaling the Aquadex platform.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
